Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
LetterLetters: Observations

Hyperhomocysteinemia and Increased Risk of Retinopathy

A cross-sectional, case-control study in patients with type 2 diabetes

Aneliya Parvanova, Ilian Iliev, Borislav D. Dimitrov, Federica Arnoldi, Jelka Zaletel, Giuseppe Remuzzi, Piero Ruggenenti
DOI: 10.2337/diacare.25.12.2361 Published 1 December 2002
Aneliya Parvanova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Ilian Iliev
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Borislav D. Dimitrov
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Federica Arnoldi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Jelka Zaletel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Giuseppe Remuzzi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Piero Ruggenenti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site

A cross-sectional, case-control study in patients with type 2 diabetes

Increased total plasma homocysteine (tHcy) level—secondary to excessive alcohol intake, cigarette smoking, or deficiency of methylene-tetrahydrofolate reductase—is one new identified risk factor for atherosclerotic cardiovascular diseases and for macrovascular complications of diabetes (1,2). Homocysteine (Hcy)-induced vascular damage is probably initiated by reactive oxygen species formed during Hcy auto-oxidation in plasma and results in decreased nitric oxide production, platelet activation, impaired arterial vasodilatation, and isolated systolic hypertension (1).

To assess whether hyperhomocysteinemia is also an independent risk factor for microvascular complications, we cross-sectionally studied the relations among tHcy levels, diabetic retinopathy (diagnosed by indirect ophtalmoscopy and retinal photography), insulin sensitivity and glomerular filtration rate (measured by euglycemic-hyperinsulinemic clamp and unlabeled iohexol plasma clearance, respectively), lipid profile, overnight urinary albumin excretion rate, and other clinical and laboratory parameters in 11 consecutive type 2 diabetic subjects with retinopathy (case subjects) and 26 age- and sex-matched type 2 diabetic subjects without retinopathy (control subjects). To limit the confounding effect of decreased tHcy clearance associated with advanced renal insufficiency, only subjects with serum creatinine ≤2.0 mg/dl were considered. Patients gave written informed consent. The Ethical Committee of the Clinical Research Center, “Aldo & Cele Daccò,” Mario Negri Institute, Italy, approved the protocol.

Altogether, 1 case subject had proliferative and 10 subjects had nonproliferative diabetic retinopathy. Prevalence of hyperhomocysteinemia (54.5 vs. 26.9%) and tHcy levels (17.2 ± 6.6 vs. 12.3 ± 4.1 μmol/l, P < 0.05) were higher in case than in control subjects. Case subjects also had longer diabetes duration (171 ± 96 vs. 73 ± 75 months), lower BMI (27 ± 5 vs. 31 ± 5 kg/m2), higher systolic blood pressure (155 ± 15 vs. 145 ± 12 mmHg) and albumin excretion rate (412 ± 600 vs. 212 ± 385 μg/min), and were more frequently micro- or macroalbuminuric (P < 0.05 for all comparisons). Age, sex distribution (with a male prevalence in both groups), smoking habit, HbA1c level, diastolic blood pressure, insulin sensitivity, lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides), serum creatinine, glomerular filtration rate, and antidiabetic and antihypertensive treatments were comparable in both groups. At univariate logistic regression analysis, only longer duration of diabetes, higher systolic blood pressure, and increased tHcy levels were associated with diabetic retinopathy. Glomerular filtration rate was not related to diabetic retinopathy (P > 0.05). At multivariate forward stepwise logistic regression, tHcy (β = 4.47, P = 0.019), diabetes duration (β = 2.10, P = 0.009), and systolic blood pressure (β = 0.09, P = 0.020) were independent markers of diabetic retinopathy. Altogether, they predicted the disease with 86.5% accuracy (model χ2 = 23.19, P = 0.0001).

Thus, hyperhomocysteinemia is associated with an increased risk of diabetic retinopathy and clusters with longer diabetes duration and systolic hypertension as an independent marker. The finding that case subjects had higher albumin excretion rates than control subjects and were more frequently micro- or macroalbuminuric suggests that hyperhomocysteinemia is also an indicator of overall microvascular damage in type 2 diabetes.

Hcy evaluation may serve to identify diabetic patients predisposed to sight-threatening complications who may benefit from intensified screening and treatment strategies, including folic acid and vitamin B6 and B12 supplements, aimed to limit or prevent the incidence and progression of micro- and macrovascular complications.

Footnotes

  • Address correspondence to Piero Ruggenenti, MD, “Mario Negri” Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11-24125 Bergamo, Italy. E-mail: manuelap{at}marionegri.it.

  • DIABETES CARE

References

  1. Gerhard GT, Duell B: Homocysteine and atherosclerosis. Curr Opinion Lipidol 10: 417–428, 1999
  2. Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 338: 1042–1050, 1998

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.